Jim Simons
CTNM

Jim Simons’s Contineum Therapeutics CTNM Stock Holding History

Jim Simons’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$906K Buy
69,400
+12,300
+22% +$165K ﹤0.01% 2322
2025
Q4 		$653K Buy
57,100
+15,900
+39% +$181K ﹤0.01% 2470
2025
Q3 		$484K Buy
41,200
+26,796
+186% +$216K ﹤0.01% 2809
2025
Q2 		$57.2K Buy
+14,404
New +$62.6K ﹤0.01% 3376

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jim Simons's CTNM Position: Q1 2026 in Review

Jim Simons increased its Contineum Therapeutics (CTNM) stake by 22% in Q1 2026, buying an estimated $165K and bringing the position to 69,400 shares worth $906K. The position accounts for ﹤0.01% of the portfolio, ranked #2322.

Jim Simons first reported a position in CTNM in Q2 2025 and has held it in 4 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Jim Simons held 69,400 shares of Contineum Therapeutics worth $906K as of Q1 2026.
  • Jim Simons bought 12,300 Contineum Therapeutics shares in Q1 2026, an estimated $165K.
  • Contineum Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2322 holding.
  • Jim Simons first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.